Tonix Pharmaceuticals to Participate in BIO-Europe Digital 2021
October 21 2021 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, announced
today that Seth Lederman, M.D., President and Chief Executive
Officer of Tonix, will deliver a Company presentation and host
one-on-one meetings during the BIO-Europe 2021 event, being held
virtually October 25-28, 2021. The Company’s presentation will be
available on demand to registered participants through the
conference website. Additional meeting information can be found on
the BIO-Europe 2021 website at BIO-EUROPE.
Tonix Pharmaceuticals Holding
Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
small molecules and biologics to treat and prevent human disease
and alleviate suffering. Tonix’s portfolio is primarily composed of
immunology and central nervous system (CNS) product candidates.
Tonix’s immunology portfolio includes a COVID-19 platform of
product candidates to prevent and treat COVID-19, to treat Long
COVID as well as to detect functional T cell immunity to COVID-19.
Tonix’s lead vaccine candidate for COVID-19, TNX-18001, is a live
replicating vaccine based on Tonix’s recombinant pox vaccine (RPV)
platform to protect against COVID-19, primarily by eliciting a T
cell response. Tonix reported positive efficacy data from animal
studies of TNX-1800 in the first quarter of 2021 and expects to
start a Phase 1 study in humans in the first half of 2022.
TNX-35002 (sangivamycin) is a small molecule antiviral drug to
treat acute COVID-19 and is in the pre-Investigational New Drug
(IND) stage of development. TNX-102 SL3 (cyclobenzaprine HCl
sublingual tablets) is a small molecule drug being developed to
treat Long COVID, a chronic condition, and is also in the pre-IND
stage. Finally, Tonix is developing TNX-21004, an in
vivo diagnostic to measure the presence of functional T cell
immunity to COVID-19. Tonix intends to initiate a first-in-human
clinical study of TNX-21004 in the fourth quarter of 2021,
pending IND clearance. Tonix’s immunology portfolio also includes
biologics to address immunosuppression, cancer, and autoimmune
diseases. The Company’s CNS portfolio includes both small molecules
and biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL3, is in
mid-Phase 3 development for the management of fibromyalgia.
1TNX-1800 is an investigational new biologic and
has not been approved for any indication. TNX-1800 is based
on TNX-801, live horsepox virus vaccine for percutaneous
administration, which is in development to protect against smallpox
and monkeypox. TNX-801 is an investigational new biologic and has
not been approved for any indication.
2TNX-3500 is an investigational new drug at the
pre-IND stage of development and has not been approved for any
indication.
3TNX-102 SL is an investigational new drug and
has not been approved for any indication.
4TNX-2100 is an investigational new biologic and
has not been approved for any indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, the
risks related to the operation of research and manufacturing
facilities, risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval, and
commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2020, as filed
with the Securities and Exchange Commission (the “SEC”) on March
15, 2021, and periodic reports filed with the SEC on or after the
date thereof. All Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182
Olipriya Das, Ph.D. (media)Russo
PartnersOlipriya.Das@russopartnersllc.com (646) 942-5588
Peter Vozzo (investors)ICR
Westwickepeter.vozzo@westwicke.com(443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024